Physician profile
Jaydev Avashia
NPI 1144225939
$837.59
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $59.34 · 2021: $143 · 2022: $16.75 · 2023: $72.30 · 2024: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $194.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $175.34 | 2023-2024 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $101.73 | 2019-2022 | |
| Emd Serono, INC. | $97.98 | 2019-2021 | |
| Horizon Therapeutics Plc | $85.97 | 2019 | |
| Partner Therapeutics, INC. | $72.68 | 2019 | |
| Merck Sharp & Dohme LLC | $47.58 | 2019 | |
| Astellas Pharma US INC | $47.31 | 2021 | |
| Amgen INC. | $38.66 | 2019 | |
| Janssen Biotech, INC. | $35.86 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $33.52 | 2019 | |
| Genzyme Corporation | $19.10 | 2023 | |
| Glaxosmithkline, LLC. | $17.26 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.12 | 2019 | |
| Dova Pharmaceuticals | $13.57 | 2019 | |
| Pfizer INC. | $13.03 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $12.12 | 2019 | |
| Secura Bio, INC. | $9.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaydev Avashia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.